Featured News
Press Release
Alzheimer’s Association Welcomes Continued Progress in Alzheimer’s Treatment with FDA Approval of Leqembi Subcutaneous Starter Dose
Chicago, July 13, 2026 — The Alzheimer’s Association welcomes today’s U.S. Food and Drug Administration (FDA) action to approve a subcutaneous starter dose of Leqembi® (lecane...
All News
AIM Blog
The Mammogram Moment
In 1986, only about 14% of women in the U.S. were getting mammograms. The test existed. It worked. But Medicare...
Press Release
House Subcommittee Acts to Expand Dementia Training for Health Care Providers
Washington, D.C., May 13, 2026 — The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM) applaud today’s markup of the...
AIM Blog
The Phone Call That Could Change Everything for Alzheimer’s
I’m asking you to do one thing in the next two weeks: pick up the phone. In this second video...
AIM Blog
Introducing The ASAP Minute
A simple blood test can now detect Alzheimer’s years before symptoms appear. It’s accurate. It’s affordable. It’s available. But most...
AIM Blog
Recognizing AIM’s May Advocate of the Month: Sean Terwilliger
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
AIM Blog
9 in 10 Americans Want Medicare to Cover Alzheimer’s Blood Tests. Congress Should Listen.
Forty years ago, only 14% of women were getting mammograms. The test existed. It worked. But Medicare didn’t cover it...